cancer

Lilly Shares Drop As Cancer Therapy Lartruvo Fails Study

Lilly Shares Drop As Cancer Therapy Lartruvo Fails Study

Eli Lilly & Co. (NYSE: LLY) said on Friday its cancer treatment Lartruvo, approved on an accelerated basis in 2016, failed to improve patient survival in a long-term study and will no longer be prescribed, driving shares down 3%.The Company said..

Juno Shares Surge on Celgene’s $9 Billion Acquisition

Juno Shares Surge on Celgene’s $9 Billion Acquisition

Juno Therapeutics Inc. (NASDAQ: JUNO) shares continued to surge on Monday after Celgene Corp. (NASDAQ: CELG) had entered into an agreement to acquire Juno for a total of $9 billion or $87 per share. Juno shares rose 27 percent during Monday&rsq..